We believe serious diseases deserveserious attention
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. A leader in muscle biology research with more than 60 publications, over 50 clinical trials, and hundreds of issued patents, Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Cytokinetics was founded in 1998 by pioneers in the field of muscle biology. Over the years, our company has developed an unparalleled expertise, keeping it at the forefront of drug discovery and development for diseases impacting muscle performance. Muscle plays a critical role in everyday physical functionality, including proper circulation, movement, and even the ability to breathe. As a result, conditions or syndromes that lead to dysfunction of muscle have serious consequences on survival and well-being.
Cytokinetics takes a purpose-driven approach by leveraging our unique muscle biology expertise to engineer compounds with specific characteristics aimed at treating diseases that impact muscle function. By directly targeting the sarcomere, the foundation of muscle contraction, the treatments we are developing have the potential to preserve and extend independence and self-reliance in people suffering from debilitating diseases. Cytokinetics is dedicated to helping underserved patient populations which lack effective therapies.
Cytokinetics scientists have discovered a robust pipeline of small molecule muscle activators and inhibitors; omecamtiv mecarbil, a cardiac myosin activator; reldesemtiv, a fast skeletal muscle troponin activator (FSTA); CK-274 and CK-271, cardiac myosin inhibitors; AMG 594, a cardiac troponin activator; and CK-601, a next-generation FSTA. Our muscle biology drug discovery and development platform has great potential for many other diseases and medical conditions characterized by muscle weakness, fatigue, or diminished muscle function.